The global pharmaceutical industry experienced a 20% rise in company filings sentiment in Q2 2023 compared with the previous quarter, according to GlobalData’s analysis of over 1,346 pharmaceutical company filings. GlobalData’s Healthcare Expenditure and Pharmaceutical Sales Analysis report provides an outlook of the global pharmaceutical sector and its key drivers through comprehensive analysis. It includes insights on technology, patent expirations, M&A, and healthcare policy reforms. Buy the report here.

Notably, in Q2 2023 the average sentiment rose from 0.40 to 0.48, indicating a more positive outlook for the industry. This followed a 5% quarter-on-quarter increase in Q1 2023.

GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative or neutral. Starting at 100 in 2020, an index over 100 is more positive.

Top companies by company filings sentiment in the global pharmaceutical industry, Q2 2023 (Sentiment score)

For further understanding of GlobalData's Healthcare Expenditure and Pharmaceutical Sale Analysis, buy the report here.

This content was updated on 5 August 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.